Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
- 2025-09
-
In the search for more specific
2024-01-08
In the search for more specific inhibitors of uptake2, Iversen and Salt (1970) speculated that steroids may potentiate the actions of catecholamines on vascular smooth muscle by inhibiting uptake2-mediated catecholamine clearance of the transmitters. They went on to demonstrate that a variety of ste
-
The subdivision of HT receptors
2024-01-08
The subdivision of 5-HT receptors started in the 1950s by Gaddum and colleagues, when they realised that in the guinea pig ileum, the effects of 5-HT could be blocked in part by morphine (M), and in part by dibenzyline (D). Gaddum and Picarelli proposed two receptor classes, 5-HT M and 5-HT D (1957)
-
87 59 australia br Role of LPA in tumor angiogenesis and
2024-01-08
Role of LPA in tumor angiogenesis and skeletal metastasis The angiogenesis switch is essential for tumor expansion and escape of tumor 87 59 australia from the primary site and forming distant metastases. Evidence for the role of LPA2 and LPA3 in the mobility of endothelial cells and the formati
-
The SKOV and SKOV TR cells were exposed to stepwise
2024-01-08
The SKOV3 and SKOV3TR 92 3 mg were exposed to stepwise increased concentration of paclitaxel with or without a different concentration of autophagy inhibitor (3-MA or HCQ) to further evaluate whether suppression of autophagy affected the growth and drug sensitivity of ovarian cancer cells in vitro.
-
Several approved and or experimental drugs together with
2024-01-08
Several approved and/or experimental drugs, together with natural compounds, have been reported to induce autophagy in different cancer types [70], [71], [72] (Table 1). In the next paragraphs, we will review more in detail a group of these agents selected in relation to their promising future outco
-
A contribution of V ATPase subunits specifically to phagosom
2024-01-08
A contribution of V-ATPase subunits specifically to phagosome-lysosome fusion was uncovered by Peri and Nüsslein-Volhard who described that depletion of the VO subunit a1 in zebrafish interferes with phagosome maturation in microglial p-nitro-Cyclic Pifithrin-α (Peri and Nusslein-Volhard, 2008). Ho
-
According to the diversity in molecular skeletons aromatase
2024-01-08
According to the Phosphatase Inhibitor Cocktail (2 Tubes, 100X) in molecular skeletons, aromatase inhibitors can be categorized into two types: steroidal and non-steroidal blockers [6]. Steroidal AI (e.g., exemestane in Fig. 1) derived from the substrate androstenedione interacts with aromatase thr
-
Although the interactions of PhLP with G and its other
2024-01-08
Although the interactions of PhLP with Gβγ and its other partners have been convincingly documented through in vitro studies, it is not clear how PhLP controls Parthenolide mg signaling in vivo. C. elegans provides a powerful genetic model to analyze Phosducin function and study its interacting par
-
ALK fusion positive NSCLC is clinically actionable because i
2024-01-05
ALK fusion-positive NSCLC is clinically actionable because it can be targeted by several FDA-approved drugs, including the first generation TKI crizotinib, which is a dual inhibitor to MET and ALK [15], and the second generation inhibitors, alectinib and ceritinib, both of which are highly-selective
-
Both subcutaneous s c and mucosal administration
2024-01-05
Both subcutaneous (s.c.) and mucosal administration of short synthetic peptide derivatives of AChR prevent the onset of EAMG, but do not treat ongoing EAMG [80], [81], [82], [83], [84], [85]. The selection of peptides for treatment is mainly based on the identification of immunodominant T- and B-cel
-
To date more than different mutations
2024-01-05
To date, more than 50 different mutations in the gene have been described (Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff: SRD5A2 Gene: http://www.hgmd.cf.ac.uk). Most of them are missense mutations but premature stop codons and deletions leading to non-functional or su
-
The role of DHT in early
2024-01-05
The role of DHT in early teleost embryogenesis is not entirely clear or established, however additional studies that treat fish embryos to DHT or to specific srd5a inhibitors at critical stages of development (i.e. prior to sex differentiation) will shed light on the early functions of this androgen
-
Endoplasmic reticulum ER stress resulting from accumulation
2024-01-05
Endoplasmic reticulum (ER) stress resulting from accumulation of misfolded proteins in ER lumen stimulates a chain of adaptive responses termed as the unfolded protein response (UPR). Glucose related protein (GRP78/BiP), key ER chaperone essential for the activation of the ER-transmembrane signaling
-
The downstream targets of ATR involved in
2024-01-05
The downstream targets of ATR involved in mediating human telomerase recruitment have not yet been identified. Under stalled fork conditions, activated ATR is able to phosphorylate and activate ATM (Stiff et al., 2006, and Figures 4C and 4D); whether this Dioscin of ATM participates in a positive f
-
br STAR Methods br AMPK A Therapeutic Target
2024-01-04
STAR★Methods AMPK: A Therapeutic Target in the β Cell? Loss of pancreatic β cell function is a hallmark of the transition to a diagnosis of T2DM (see Glossary) 1, 2, 3, 4. AMPK activation has gained attention for the treatment of hyperglycemia in prediabetes as an insulin-sensitizing agent bec
15889 records 199/1060 page Previous Next First page 上5页 196197198199200 下5页 Last page